PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
|Webcasts|September 27, 2020
Layer by Layer: The Fundamentals of Multi-Layer Tableting
Author(s)JRS PHARMA
***Live: Tuesday, Oct. 27, 2020 *** Multi-layer tableting offers an inexpensive and straightforward solution for a variety of challenging formulations. Learn how multi-layer formulations compare to traditional methods, gain insight to the multi-layer tableting process, and crucial tips to formulating and manufacturing robust multi-layer tablets. ***On demand available after final airing until Oct. 27, 2021***
Register free:
Event Overview:
Multi-layer tableting offers an inexpensive and straightforward solution for a variety of challenging formulations. Enabling multi-phasic release systems, combinations of incompatible APIs, and gastro-retentive tablets, this under-utilized method provides efficiency and cost-savings compared to more popular complex processes.
This webcast will compare multi-layer formulation options to traditional methods, providing a step-by-step guide to the multi-layer tableting process, and offering crucial tips to formulating and manufacturing robust multi-layer tablets. Learn how tooling considerations, excipient selection, layer design, and tamping force adjustment can impact overall tablet robustness, as well as layer-to-layer adhesion.
Key Learning Objectives:
- Understand the basics of multi-layer tablet formulations and its drug delivery possibilities.
- Follow step-by-step through the multi-layer tableting process.
- Learn essential tips for creating robust multi-layer tablets, from tooling considerations, excipient selection, layer design, to tamping force adjustment.
Speaker: Anthony Carpanzano, Director of R&D, JRS PHARMA
Time and Date: Tuesday, Oct. 27, 2020 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST
On demand available after final airing until Oct. 27, 2021
Sponsor: JRS PHARMA
Register free:
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.